← Leaderboards
David Wishart
Sloan-Kettering Inst Can Research
$3,311,142
Attributed
$8,633,875
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,633,875 · 4
By mechanism
U01$4,768,289 · 1
UH3$2,258,511 · 1
U2C$1,245,812 · 1
UG3$361,263 · 1
Top collaborators
- Oliver Fiehn5 shared
- Lee E Goldstein5 shared
- Rima F Kaddurah-Daouk5 shared
- Olusegun Isaac Alatise4 shared
- T Peter Kingham4 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Lawrence Stuart Engel$3,455,390
- T Peter Kingham$2,940,023
- Gabriela Chiosis$23,584,161
- Olusegun Isaac Alatise$2,073,530
- Kun Huang$9,441,021
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposMetabolomicsBiobankMetabolicSpecimenSamplingMetabolomeDatabasesIndustryMedicineBiochemicalMolecularResearch PersonnelResourcesCommunitiesExposure ToDietBiological MarkersFundingGenerationsTechnologyProgramsEngineeringBase
Grant awards (12)
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory$2,107,225
U01 · FY2025 · AG
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory$79,380
U01 · FY2025 · AG
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory$55,842
U01 · FY2025 · AG
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory$26,460
U01 · FY2025 · AG
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory$2,499,382
U01 · FY2024 · AG
Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries$740,348
UH3 · FY2022 · CA
Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries$751,117
UH3 · FY2021 · CA
Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries$767,046
UH3 · FY2020 · CA
Computational Core$494,853
U2C · FY2020 · ES · contact PI
Computational Core$370,806
U2C · FY2019 · ES · contact PI
Computational Core$380,153
U2C · FY2018 · ES · contact PI
Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries$361,263
UG3 · FY2018 · EB